ipharmacy

Drug Recall

FDA Drug Recall: MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, B...

U.S. Food and Drug Administration
September 9, 2026
ID: D-0806-2026

Drug Enforcement Report Details

Recall Number	D-0806-2026
Recalling Firm	Baxter Healthcare Corporation
Classification	Class II
Voluntary / Mandated	Voluntary: Firm initiated
Distribution Pattern	US Nationwide; Puerto Rico; and Chile.
Status	Ongoing

Product Description

MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12.

Reason for Recall

CGMP Deviations

Code Information

Lot # NC188630, NC188708, NC188791, NC188845, NC188876, NC188968, Exp Date: 12/31/2027; Lot # NC193719, NC193849, Exp Date: 04/30/2028; Lot # NC194051, NC194105, Exp Date: 05/31/2028; Lot # NC195171, Exp Date: 06/30/2028.

Content syndicated from the U.S. Food and Drug Administration (FDA) drug enforcement reports database.

View Official Announcement on FDA.gov